Adenoid cystic carcinoma of the breast with late recurrence and high-grade transformation

  1. Gowtham Vasudevan 1,
  2. Ann Mary John 2,
  3. Vijaykumar D K 3 and
  4. Archana George Vallonthaiel 2
  1. 1 General Surgery, Amrita Institute of Medical Sciences, Cochin, Kerala, India
  2. 2 Pathology, Amrita Institute of Medical Sciences, Cochin, Kerala, India
  3. 3 Breast Clinic and Surgical Oncology, Amrita Institute of Medical Sciences, Cochin, Kerala, India
  1. Correspondence to Dr Archana George Vallonthaiel; dr.archanageorge@gmail.com

Publication history

Accepted:30 Jan 2023
First published:09 Feb 2023
Online issue publication:09 Feb 2023

Case reports

Case reports are not necessarily evidence-based in the same way that the other content on BMJ Best Practice is. They should not be relied on to guide clinical practice. Please check the date of publication.

Abstract

Breast cancers have broad histological subtypes with varied molecular expression, which determines the management. Although ductal and lobular breast carcinomas constitute the significant 90% of these tumours, other subtypes constitute about 10% of breast cancers. Adenoid cystic carcinoma (AdCC) is a salivary gland-type tumour described in breast, constituting less than 1% of all breast carcinomas. These tumours have a favourable prognosis and are surgically managed by either lumpectomy or mastectomy. Solid-basaloid and AdCC with high-grade transformation are the sporadic subtypes of AdCC, in addition to the classic type. We report a case of recurrent AdCC which was surgically managed by modified radical mastectomy initially and presented with recurrence and high-grade transformation 11 years later.

Background

Adenoid cystic carcinoma (AdCC) is a tumour commonly of the salivary gland origin and AdCC in the breast constitutes less than 1% of all breast carcinomas.1 When presented, these tumours are surgically managed by either lumpectomy or mastectomy as they are considered to have a favourable prognosis1 (table 1). Classic type, solid-basaloid type and AdCC with high-grade transformation are the morphological subtypes of AdCC. However, the prognosis of subtypes of AdCC other than classic subtype is not clear due to rarity of cases. Studies state that a high-grade transformation of higher malignancy grade (previously known as a de-differentiated component) worsens the prognosis.2 3 Also, each component (the low grade and the transformed high grade) may respond differently to the type of appropriate adjuvant treatment, requiring specific chemotherapy or radiotherapy (RT) targeting each component.2 3

Table 1

Comparison of surgical managment, adjuvant treatment and reurrence rates of Adenoid cystic carcinoma of Breast

S. no Article Total female patients in the study Number of recurrences after complete surgical resection of local tumour Number of cases with lumpectomy as initial surgery (Among those recurred) Number of cases with mastectomy as initial surgery (simple or modified radical) (Among those recurred) Number of adjuvant therapy (Among those recurred) 5-year recurrence (in %) 10-year recurrence (in %) Range of time for recurrence (in years)
1 Millar et al 1 18 6 4 2 1 6 31 2.3–11.9
2 Arpino et al 11 28 1 1 0 0 0 3 6

High-grade transformation in AdCC is well described in salivary gland with over 48 cases in the literature4; however, it is rare in breast. Case reports where AdCC of the breast was associated with invasive breast carcinoma or small cell carcinoma or malignant adenomyoepithelioma are there in literature.5 However, these are more like synchronous primary tumours rather than high-grade transformation in the true sense. To the best of our knowledge, we believe this is the first case to use the term ‘adenoid cystic carcinoma with high-grade transformation’ in the breast, since its inclusion in the WHO fascicle in 2019.

Case presentation

A woman in her 60s presented with a left chest wall lump for 1 year and pain of 2-week duration. Twelve years ago, she had a lump in the upper outer quadrant of her left breast and underwent a lumpectomy at an outside hospital. It was a T1 tumour and histology was reported as AdCC of the breast with positive margins. Hence, she came to our hospital for further management. A slide review at our institute confirmed the diagnosis of AdCC; however, blocks were not available to perform immunohistochemistry (IHC). The patient opted for a mastectomy and eventually underwent a mastectomy with axillary dissection. Histopathology of the mastectomy specimen showed no residual tumour. She was started on tamoxifen empirically for 5 years, per our policy for cases with unknown receptor status. She was on regular follow-up until 4 years ago and was lost to follow-up thereafter.

She had paroxysmal supraventricular tachycardia for the last 15 years and dyslipidaemia for the last 2 years. No other comorbidities or family history of malignancy was present.

Examination showed a 5×5 cm firm-to-hard lump with irregular margins and reddened skin confined to the lateral end of the previous surgical scar (figure 1). There was associated local rise of temperature and tenderness. Further ultrasonography and guided core biopsy of the lesion were also performed.

Figure 1

Clinical picture showing mass in the left chest wall close to axilla measuring 5×5 cm.

Investigations

A mammogram of the right breast showed heterogeneously dense breast parenchyma. There were no suspicious masses, architectural distortion or calcification in the right breast as confirmed on tomosynthesis sequences.

Left chest wall ultrasound revealed an irregular hypoechoic solid mass with irregular margins measuring 3.7×3.1×4 cm. Another smaller adjacent lesion was also noted measuring 2.1×1.4×3 cm. The masses had heterogeneous echotexture with intralesional vascularity and posterior enhancement. Radiologically, the masses were reported as Breast Imaging Reporting And Data System- BIRADS 4c. Possibility of recurrent AdCC or angiosarcoma was considered on radiology.

Histopathological examination of the specimen obtained by core biopsy showed a poorly differentiated neoplasm where cells were arranged in sheets with extensive areas of necrosis. The cells had scant cytoplasm with ovoid hyperchromatic nuclei. No cribriform areas suggestive of AdCC were seen. Possibility of small cell carcinoma was considered.

IHC for cytokeratin showed focal positivity, while IHC for CD34, CD31, synaptophysin and LCA was negative, ruling out angiosarcoma, lymphoma and small cell carcinoma. Even though morphology was not suggestive of AdCC, IHC for CD117 and p63 was performed given the previous diagnosis. CD117 turned out to be positive while myoepithelial marker p63 was negative. Possibility of AdCC recurrence was considered in view of CD117 positivity; however, the present case did not show diffuse cytokeratin positivity or highlight myoepithelial cells on p63, unlike a typical case of AdCC (figure 2).

Figure 2

Trucut biopsy showing tumour cells arranged in sheets with areas of necrosis. No cribriform areas seen (A, H&E 10×); tumour cells show strong positivity for CD117 (B, 40×); tumour cells with focal cytokeratin positivity (C, 40×).

Positron emission tomography-CT was then performed, and it showed thickening in chest wall (figure 3). Because of absent distant metastasis, we proceeded with wide local excision of the lesion. Surgical resection involved excision of the lump along with the underlying serratus anterior fibres over which the tumour was resting.

Figure 3

Positron emission tomography-CT showing the tumour in the left chest wall.

On gross examination of the excised sample, two distinct lesions were identified abutting each other (figure 4). One of the lesions was soft to firm in consistency, measuring 4.5×4×4 cm (lesion 1) and the other lesion was firm measuring 3×2.5×2 cm (lesion 2). On microscopy, sections studied from two lesions showed different morphological patterns. Lesion 1 showed neoplastic cells arranged in sheets with extensive necrosis and brisk mitosis. The cells had scant cytoplasm and ovoid vesicular nuclei with few showing conspicuous nucleoli. Solid-basaloid morphology was not seen. Lesion 2 revealed neoplastic cells arranged in lobules and nests separated by fibrous septae. Within the nests, cells showed cribriform and solid pattern. Cells had round-to-ovoid vesicular nuclei with prominent nucleoli and eosinophilic cytoplasm.

Figure 4

Gross examination showed vaguely circumscribed nodular soft lesion measuring 4.5×4×4 cm (lesion 1, black arrow); another nodular firm lesion seen measuring 3×2.5×2 cm (lesion 2, orange arrow).

Eosinophilic basement membrane-like material was noted in luminal spaces. Areas of necrosis and frequent mitosis were also noted (figure 5). The lesions showed abrupt transition between each other (figure 6). IHC on lesion 2 (with classic AdCC morphology) showed CD117 positivity in luminal cells, p63 positivity in myoepithelial cells and diffuse cytokeratin positivity. IHC for oestrogen receptor, HER2/neu, synaptophysin and CD56 was negative. Ki67 was around 15%–20%. IHC in lesion 1 (with poorly differentiated morphology) showed focal CD117 staining with negative p63 staining. Cytokeratin and synaptophysin positivity were noted in occasional cells. Oestrogen receptor, HER2/neu and CD56 were negative with Ki67 of 70%–80%. The cribriform areas in lesion 2 raise the differential of an invasive cribriform carcinoma (ICC). However, CD117 positivity and oestrogen receptor negativity with positive p63 excluded ICC. Considering the morphological and IHC findings, we had areas of classic AdCC and distinct areas of poorly differentiated carcinoma leading to the diagnosis of AdCC of the breast with high-grade transformation. Margins of excision were free of tumour.

Figure 5

Tumour cells arranged in cribriform pattern, suggestive of classic adenoid cystic carcinoma (A: H&E 10×); tumour cells with CD117 positivity (B: 40×); p63 positivity (C: 40×); CK positivity (D: 40×) and low Ki67 (E: 40×). Tumour cells arranged as sheets with areas of necrosis suggestive of high-grade transformation (F: H&E 10×); tumour with focal CD117 positivity (G: 40×); negative p63 (H: 40×); negative CK (I: 40×) and high Ki67 (J: 40×).

Figure 6

Area of abrupt transition from classic morphology to high-grade area (A: H&E 4×; B: H&E 10×).

Treatment

Her case was discussed in multidisciplinary tumour board. Because of the long disease-free interval, absence of distant metastasis and the patient’s reluctance to undergo chemotherapy, it was decided to withhold chemotherapy. However, given the size and recurrent nature, local RT was offered. She underwent adjuvant RT with 50 Gy/25# over 5 weeks.

Outcome and follow-up

She tolerated the treatment well and during a follow-up CT scan after 1 year, she was detected to have local recurrence and distant metastatic nodules in both lungs. However, she decided to continue treatment elsewhere.

Discussion

AdCC is one of the morphological subtypes of breast carcinoma, classified under salivary gland-type tumour in WHO classification of breast tumours.5 AdCC of the breast was first described by Geschickter in 1945.6 It is composed of epithelial and myoepithelial components arranged in cribriform, tubular and solid patterns. AdCC is characteristically associated with MYB-NFIB fusion.5 On histology, AdCC of the breast is divided into classic AdCC, solid-basaloid AdCC and AdCC with high-grade transformation as per recent edition of the WHO.5 The previous edition of the WHO included only the classic subtype.7 Classic type is characterised by cribriform and tubular structures with pseudolumina formation.5 Depending on the growth pattern (on the amount of solid component), classic AdCC is further categorised into grade 1–3. The presence of necrosis, high mitotic rate and the loss of the biphasic ductal-myoepithelial differentiation indicate high-grade transformation in AdCC.2 The term de-differentiated is more apt for mesenchymal tumours. In contrast, ‘the term high-grade transformation’ is used in epithelial tumours where the high-grade component is still recognisable as carcinoma. AdCC with high-grade transformation has been well studied in the salivary glands. However, this has not been well delineated in the breast.

In the breast, rare cases of AdCC associated with high-grade carcinomas are there in the literature, including cases of AdCC with small cell carcinoma, invasive ductal carcinoma, spindle cell carcinoma and malignant adenomyoepithelioma.5 However, these are multiple primary tumours rather than high-grade transformation of AdCC. In the current case, CD117 was also focally positive implying that it is a transformed component. Seethala et al has reviewed 11 cases of AdCC with high-grade transformation in the salivary gland, involving sinonasal mucoserous glands, submandibular glands and palate.8 The median age of their patients was 61 years. There was strikingly increased propensity for lymph nodal metastasis in AdCC with high-grade transformation; however, no nodal metastasis was seen in our case. Poorly differentiated cribriform adenocarcinoma and solid undifferentiated carcinomas were the typical morphologies of the transformed component. They suggest that sheet-like growth pattern and absence of myoepithelial layer are the features to differentiate AdCC with high-grade transformation from grade 3 classic AdCC. CD117 was found to be positive in both components of the cases in the series, with marked elevation of Ki67 in the transformed component. The present case fulfils these criteria by having solid architecture, absence of myoepithelial cells and high Ki67. These patients were managed with RT, chemotherapy and neck dissection in addition to surgical excision. During follow-up, two cases had local recurrence, two cases had distant metastasis to the lung and one to the soft tissue of shoulder with a median overall survival of 12 months, compared with median survival of 3 years in grade 3 classic AdCC. However, this survival difference was only seen in some cases in this series. So, there are no clear-cut data on survival of AdCC with high-grade transformation, even in salivary gland tumours.

AdCC of the breast typically presents as a slowly growing lesion.9 Classic AdCC shows higher survival rates than invasive breast carcinoma.5 It is associated with a favourable prognosis despite its triple negative hormonal status9 and most guidelines recommend surgical management. Adjuvant chemotherapy is advocated for lymph node metastasis (greater than micro-metastasis), high tumour grade or tumour size >3 cm,10 and radiation therapy is employed for patients opting for breast conservation or with positive nodes. Nodal metastasis and distant metastasis are uncommon.9 Distant metastasis is more common in the lung followed by metastasis to the liver, kidney and bone.9

Millar et al in a study on management of recurrent AdCC showed that the recurrence rate of AdCC was 31% with time to recurrence ranging from 2.3 to 11.9 years. They also reported distant metastasis including metastasis to the brain and bone. Of the six cases that recurred, two had undergone mastectomy and the rest (four) had lumpectomy initially.1 Our case also recurred after 11 years, highlighting the importance of long-term surveillance after surgical resection of the primary. Studies report that recurrences occur only in the initial 10-year period and an annual follow-up with X-ray up to 10 years after treatment.11 However, considering how cases with recurrences after 10 years have been reported, we would like to emphasise the need for surveillance cut-off to be extended to 15 years or more.

Since AdCC with high-grade transformation in the breast is a recent and rare entity, no data on the survival rate, metastatic potential, recurrence rate or behaviour to treatment exist. However, from studies in the salivary gland, AdCC with high-grade transformation appears to be more aggressive than grade 3 (solid) AdCC. Hence, it is important to recognise and report any proportion of transformed area present. In the current case, multidisciplinary tumour board discussion was conducted, and surgery followed by RT was decided. In case of future recurrence/distant metastasis, the possible role of targeted therapy against c-KIT needs to be considered.

To conclude, we present a case of AdCC which recurred after 11 years and showed high-grade transformation at recurrence. Sampling from the transformed area led to the diagnostic difficulty in the core biopsy specimen. This case highlights the importance of awareness of the late recurrence that can occur in AdCC and the relatively new subtype of AdCC with high-grade transformation as well as its diagnostic features.

Learning points

  • Adenoid cystic carcinoma with high-grade transformation is described in salivary gland; however, it is extremely rare in the breast.

  • Adenoid cystic carcinoma with high-grade transformation is more aggressive than grade 3/solid adenoid cystic carcinoma with increased frequency of recurrence and distant metastasis.

  • Core biopsy sampling from the transformed area can pose diagnostic difficulty.

  • Adenoid cystic carcinoma of the breast can have delayed recurrence as late as 11 years.

Ethics statements

Patient consent for publication

Footnotes

  • Contributors Supervised by VDK. The patient was under the responsibility and care of VDK. AGV was the pathologist in charge who picked up on this rare diagnosis. GV and AMJ wrote the manuscript. VDK and AGV made critical revision.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

References

Use of this content is subject to our disclaimer